ArticlePloS one2025
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Investigation of the prevalence of HER2-ultralow and the effects of HER2 status (HER2-null vs. HER2-ultralow) on survival in HER2-negative early-stage breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Mitochondrial Redox Vulnerabilities in Triple-Negative Breast Cancer: Integrative Perspectives and Emerging Therapeutic Strategies.Metabolites · 2026Review
- The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in HER2-low breast cancer has grown in recent years due to advancements in novel anti-HER2 antibody-drug conjugates. This study examined the impact of HER2-low expression on survival outcomes in triple-negative breast cancer (TNBC) of high-grade special histological type (ST) and no special type (NST) and investigated the prognostic significance of TNBC subtype (high-grade ST vs. NST) within HER2 0 and HER2-low expression subgroups. Clinicopathological and survival data of 504 patients with stage I-III TNBC, with or without neoadjuvant chemotherapy (NAC), were analyzed, including 400 patients with TNBC NST and 104 patients with high-grade TNBC ST. HER2-low status was not identified as an independent prognostic factor for survival in the overall cohort, nor within the high-grade TNBC ST and TNBC NST subgroups. Among patients who did not receive NAC, TNBC subtype (high-grade ST vs. NST) was independently associated with DDFS and DFS in the HER2 0 subgroup, but not in the HER2-low subgroup. Patients with HER2 0 high-grade TNBC ST exhibited significantly worse OS (p = 0.008), DDFS (p < 0.001), and DFS (p < 0.001) compared to those with HER2 0 TNBC NST. Among patients with either HER2 0 or HER2-low tumors treated with NAC, no significant survival difference was observed between high-grade TNBC ST and TNBC NST. These findings suggest that the prognostic impact of TNBC subtype (high-grade ST vs. NST) on survival outcomes may be modulated by HER2 status in a subset of TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.